Author Archives: Dan Stanton

Boehringer Ingelheim boosted CDMO biz through €370m spend in 2020

Boehringer Ingelheim invested in capacity at sites in Germany and Austria last year on the back of high capacity utilization and increased demand for CDMO services. While most of Boehringer Ingelheim’s revenues come from its own portfolio of human and animal therapeutics, Boehringer Ingelheim’s biopharma contract manufacturing business pulled in €837 million ($986 million) in 2020, up 6.6% on the year prior. According to the firm’s annual report, “Boehringer Ingelheim covers the entire biopharmaceutical value chain, from development of the…

Curi Bio receives $6m funding boost for human stem cell platforms

The financing will support Curi Bio’s 2D and 3D platforms, which aim to improve the predictivity of human stem cell-derived tissue for drug discovery. Curi Bio’s platform technologies use human iPSC-derived cells, tissue-specific biosystems, and AI-enabled data analytics to help accelerate the discovery of therapeutics. The Series A financing round, led by Dynamk Capital, will help grow the business and validate the tech to show the need for predictive and mature human stem cell platforms to close the gap between…

Spain’s mAbxience boosting biologics capacity with 4,000 L SUB

Biosimilar maker and CDMO mAbxience will install an ABEC 4,000 L CSR bioreactor at its site in León, Spain. mAbxience, the biologics division of Spain’s Insud Pharma group, claims its León plant is “the biggest biologic plant in Spain and the first in Europe with fully integrated single-use technology in most processes.” Now the site is set to get bigger, with a 4,000 L single-use bioreactor (SUB) system expected to be installed in the coming months, which, according to the…

WuXi Bio set for 430,000 L biomanufacturing capacity from 2024

The acquisition of CMAB Biopharma comes days after WuXi Biologics bought a Pfizer facility, months after it added a Bayer plant, and a decade after it entered the biomanufacturing space. Contract development and manufacturing organization (CDMO) is in the news again, just a week after it acquired a single-use biologics manufacturing plant in Hangzhou, China from Big Pharma firm Pfizer. This time it has entered an agreement to buy over 90% of fellow Chinese CDMO CMAB Biopharma for an undisclosed…

Fujifilm selects NC for 160,000 L mammalian plant

Infrastructure, state incentives, and proximity to an existing facility have driven CDMO Fujifilm Diosynth Biotechnologies to select Holly Springs, North Carolina as the site of its ¥200 billion biologics plant. In January, Fujifilm Corporation announced plans to invest ¥200 billion (then $2 billion, now $1.8 billion) to build a biologics facility in the US run by its contract development and manufacturing organization (CDMO) business Fujifilm Diosynth Biotechnologies (FDB). Details, including the planned mammalian cell culture capacity of 160,000 L (made…

COVID catalyst: MilliporeSigma expedites $30m French expansion

MilliporeSigma has accelerated plans to add a single-use assembly production unit at its site in Molsheim, France on the back of COVID-19 demand. The $30 million injection at the site, just west of Strasbourg, will add 18,300 square feet of cleanroom space to produce MilliporeSigma’s Mobius single-use assemblies for use in the production of both COVID-19 vaccines and other therapies. The expansion will generate more than 350 jobs. The facility will become the first European site to make the single-use…

With $58m in hand, Touchlight looks to triple DNA manufacturing capacity

Touchlight says the latest fundraising round will help increase production capacity to up to 1 kilogram of DNA per month – enough for 1 billion vaccine doses – as demand skyrockets. Hampton, UK-based firm Touchlight has raised £42 million ($58 million) through a fundraising round led by Bridford Investments Limited. The firm produces synthetic DNA used as starting material in advanced therapies including lentivirus and messenger RNA (mRNA) and says the cash injection will be used to expand production capacity,…

Pfizer exits Chinese biosimilars space, selling plant to WuXi

As part of a “difficult decision” to halt its biosimilars programs in China, Pfizer is offloading its single-use biologics manufacturing plant in Hangzhou to WuXi Biologics. Pfizer is one of the world’s largest biosimilar manufacturers, with seven commercialized products in the US alone (Inflectra, Retacrit, Nivestym, Nyvepria, Zirabev, Trazimera, Ruxience). In 2016, Pfizer took aim at the Chinese market by investing $350 million in the Hangzhou Economic Development Area (HEDA) to set up a biosimilars manufacturing facility. Five years on…

Thermo Fisher rolls out 3,000 and 5,000 L single-use bioreactors

Strong demand for large-scale single-use systems has driven Thermo Fisher to launch bioreactors with capacities beyond the standard limits. Single-use bioreactors have become a staple in the bioprocess industry, both for clinical and commercial batches. Traditionally, these have been restricted in size due to pressure challenges from the increased weight of the liquid medium in larger volume bags with 2,000 L being the upper limit. Thus, if biomanufacturers require larger volumes, they generally would run several systems in unison or…

‘mRNA has been validated’ – Pfizer looks beyond COVID

Pfizer is set to make around $15 billion from its COVID vaccine this year, but going forward the firm expects mRNA to be key in other applications. Through its partnership with BioNTech, Pfizer became the first company to receive US and EU approval for a messenger RNA-based product, namely the COVID-19 vaccine BNT162b2. Rollout of the vaccine continues across the globe and as such Pfizer has estimated it will realize approximately $15 billion in sales in 2021 alone. Speaking at…